Ravi Salgia to Organophosphorus Compounds
This is a "connection" page, showing publications Ravi Salgia has written about Organophosphorus Compounds.
Connection Strength
0.800
-
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
Score: 0.621
-
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
Score: 0.142
-
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
Score: 0.037